Rare Disease Advocates Tackle Regulatory Maze for 10,000+ Conditions

WASHINGTON – May 14, 2026 – As scientific breakthroughs continue to offer new hope, the path to delivering life-altering therapies for the more than 10,000 known rare diseases remains a formidable challenge. This week, leaders from across the rare disease ecosystem convened in the nation's capital to address this very issue, seeking to untangle the complex web of science, policy, and regulation that governs therapy development.

On Tuesday, the EveryLife Foundation for Rare Diseases hosted its biennial Scientific Workshop, an interactive forum designed to forge practical solutions. Titled, "Making What Matters Count," the event brought together patient advocates, biopharmaceutical companies, academic researchers, and officials from the U.S. Food and Drug Administration (FDA). The central mission: to strengthen and standardize the use of patient-centered approaches in a rapidly evolving regulatory environment.

For the millions of people living with a rare disease, the stakes could not be higher. While advancements in genetics and medicine are accelerating, the journey from a promising discovery in the lab to an accessible treatment is often fraught with delays and dead ends. This workshop aimed to identify and dismantle the systemic barriers that stand in the way.

The Patient at the Center of the Labyrinth

A core theme of the workshop was the critical need to meaningfully integrate the patient experience into every stage of drug development. This concept, known as Patient-Focused Drug Development (PFDD), is a formal initiative by the FDA to ensure that the perspectives, needs, and priorities of patients are captured and considered during the regulatory process.

However, putting this principle into practice for rare diseases presents unique hurdles. The journey for many patients begins with a prolonged "diagnostic odyssey," an often years-long search for a correct diagnosis that delays access to care and potential inclusion in clinical trials. Once diagnosed, the inherent rarity of their condition means patient populations are small and geographically scattered, making it difficult to conduct traditional large-scale clinical trials.

Discussions at the workshop underscored these challenges, highlighting the difficulty in developing and validating clinical endpoints—the measurable outcomes used to determine if a therapy is effective. For many rare diseases, traditional endpoints may not capture the benefits that matter most to patients, such as a small improvement in mobility or a reduction in daily pain. This is where patient experience data becomes invaluable, offering direct insight into the burdens of a disease and the real-world impact of a potential treatment. Yet, challenges persist in standardizing the collection of this data and ensuring it is given appropriate weight in regulatory evaluations.

"Ensuring that patient experience is meaningfully and consistently integrated into therapy development requires not just policy changes, but alignment, coordination, and actionable tools," said Jamie Sullivan, Senior Vice President of Policy and Advocacy for the EveryLife Foundation. "This year's discussion was designed to help us continue to identify concrete solutions that can be implemented across the ecosystem."

A Complex and Evolving Regulatory Toolkit

The regulatory landscape for rare disease therapies is more dynamic than ever. Over the past two decades, significant progress has been made, and the FDA has introduced numerous pathways, guidances, and pilot programs designed to accelerate development and review. These include expedited programs like Fast Track and Breakthrough Therapy, as well as newer initiatives like the Rare Disease Endpoint Advancement (RDEA) Pilot Program and the Support for Clinical Trials Advancing Rare disease Therapeutics (START) Pilot Program.

These tools offer unprecedented opportunities. The START program, for instance, allows for more frequent, ad-hoc communication between drug sponsors and the FDA, aiming to resolve clinical development questions quickly. The RDEA program focuses on the critical challenge of developing novel endpoints for rare disease trials.

Despite this expanding toolkit, workshop participants emphasized a persistent gap between policy and practice. A key concern raised was the variability in awareness, interpretation, and application of these regulatory flexibilities across different FDA review divisions and among drug developers. This inconsistency can create uncertainty, deter investment, and ultimately slow down the delivery of new therapies, particularly for smaller patient communities or less-resourced companies navigating the system for the first time.

The complexity has led to a sense of urgency, with advocates pointing to a recent trend of therapy rejections under the accelerated approval pathway, fueling concerns that the agency may be becoming more risk-averse in its application of regulatory flexibility.

From Dialogue to Actionable Solutions

Recognizing these challenges, the EveryLife Foundation's workshop focused on moving beyond discussion to identify concrete actions. The forum's agenda was built around several key objectives: assessing the real-world effectiveness of current regulatory pathways, identifying successful case studies that can be translated into scalable practices, and developing strategies to improve knowledge management across the ecosystem.

The ultimate goal is to enhance consistency in how rare disease products are evaluated, ensuring that the best science and the most relevant patient data inform every decision. By bringing all stakeholders to the same table, the workshop facilitates the frank dialogue needed to pinpoint where communication breaks down and where processes can be streamlined.

This collaborative approach is not new for the foundation, which has been hosting these workshops since 2010. The convenings have consistently served as a vital platform for informing policy, fostering collaboration, and building capacity within the rare disease community. Insights from past workshops have helped shape the foundation's advocacy efforts and contributed to the broader conversation around regulatory science and patient engagement.

In the coming weeks, the EveryLife Foundation will synthesize the key findings and recommendations from the event. This work will guide its ongoing policy and advocacy efforts, with the aim of advancing a more consistent, transparent, and truly patient-centered framework for rare disease therapy development. The conversations held this week are a critical step in ensuring that for every rare disease, what matters most to patients is what ultimately counts.